Daiichi Sankyo Adds To Japan's Biosimilar Fray In Two-compound Deal
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is teaming with virtual startup Coherus BioSciences for etanercept and rituximab.
You may also be interested in...
Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan
Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan